CDC20 and prostate carcinoma: Taken together, our findings unveil a negatively regulating mechanism toward GSDME by CDC20 in controlling pyroptosis signaling, indicating that the molecular targeting of CDC20 can modulate the anti-tumor immunity and the synergistic effects with α-PD-1 therapy in prostate cancer in the presence of GSDME.